توجيهات جديدة لعلاج التهاب الأمعاء أثناء الحمل

Recently, medical circles have issued new guidelines for the treatment of chronic intestinal inflammation in pregnant women, aiming to provide safer protocols that consider the health of both the mother and the fetus. The recommendations emphasize the importance of pre-pregnancy planning during periods of disease stability, along with close monitoring by specialized doctors to reduce potential complications. According to the journal "Clinical Gastroenterology," and the American Journal of Gastroenterology, the continuation of certain medications such as 5-ASA, sulfasalazine, and thiopurines is relatively safe during pregnancy and breastfeeding, while it is advised to avoid small molecule drugs several months before pregnancy and during breastfeeding, except in urgent cases. Experts also confirmed that monoclonal antibodies can continue to be used under medical supervision, which enhances the chances of disease control. Pregnancy in these cases is considered high-risk, requiring intensive care and increased vigilance in follow-up to ensure a safe delivery and avoid long-term complications.